Amersham's X-ray agent gets in-hospital edge in trial
This article was originally published in Clinica
Executive Summary
A head-to-head trial of two X-ray imaging agents made by Amersham and Bracco Diagnostics, respectively, has shown that Amersham's product leads to fewer in-hospital adverse cardiac events. The study, however, failed to establish the superiority of either agent at a later follow-up period of 30 days.